FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities-Reference-Cited by-同舟云学术

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities

Published:2014-06-03 Issue:1 Volume:14 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

L’Abbate Alberto,Lo Cunsolo Crocifissa,Macrì Ettore,Iuzzolino Paolo,Mecucci Cristina,Doglioni Claudio,Coco Michelina,Muscarella Lucia Anna,Salati Simona,Tagliafico Enrico,Minoia Carla,De Tullio Giacoma,Guarini Attilio,Testoni Nicoletta,Agostinelli Claudio,Storlazzi Clelia Tiziana

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-14-396.pdf

Reference12 articles.

1. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gaken J, Pennaneach C, Ireland R, Czepulkowski B, Pomplun S, Marsh JC, Mufti GJ: TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013, 160 (5): 660-672. 10.1111/bjh.12203.

2. Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Luno E, Steidl C, Espinet B, Vallespi T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L: Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011, 25 (1): 110-120. 10.1038/leu.2010.231.

3. Mallo M, Del Rey M, Ibanez M, Calasanz MJ, Arenillas L, Larrayoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F: Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013, 162 (1): 74-86. 10.1111/bjh.12354.

4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P: Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012, 120 (12): 2454-2465. 10.1182/blood-2012-03-420489.

5. Storlazzi CT, Albano F, Dencic-Fekete M, Djordjevic V, Rocchi M: Late-appearing pseudocentric fission event during chronic myeloid leukemia progression. Cancer Genet Cytogenet. 2007, 174 (1): 61-67. 10.1016/j.cancergencyto.2006.11.009.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics;Scientific Reports;2024-04-12

2. Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics;2023-10-13

3. Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics;2023-07-21

4. FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells;Blood Advances;2023-07-03

5. Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization;Genes;2023-06-27